| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T2 |
0-11 |
NN |
denotes |
coronavirus |
| T3 |
12-18 |
NN |
denotes |
glycan |
| T4 |
19-26 |
NNS |
denotes |
shields |
| T5 |
27-34 |
IN |
denotes |
despite |
| T6 |
35-44 |
JJ |
denotes |
extensive |
| T7 |
45-58 |
NN |
denotes |
glycosylation |
| T8 |
60-68 |
NN |
denotes |
Abstract |
| T9 |
69-75 |
JJ |
denotes |
Severe |
| T10 |
76-81 |
JJ |
denotes |
acute |
| T11 |
82-93 |
JJ |
denotes |
respiratory |
| T12 |
94-102 |
NN |
denotes |
syndrome |
| T13 |
103-104 |
-LRB- |
denotes |
( |
| T14 |
104-108 |
NN |
denotes |
SARS |
| T15 |
108-109 |
-RRB- |
denotes |
) |
| T16 |
110-113 |
CC |
denotes |
and |
| T17 |
114-120 |
NNP |
denotes |
Middle |
| T18 |
121-125 |
NNP |
denotes |
East |
| T19 |
126-137 |
JJ |
denotes |
respiratory |
| T20 |
138-146 |
NN |
denotes |
syndrome |
| T21 |
147-148 |
-LRB- |
denotes |
( |
| T22 |
148-152 |
NNS |
denotes |
MERS |
| T23 |
152-153 |
-RRB- |
denotes |
) |
| T24 |
154-167 |
NNS |
denotes |
coronaviruses |
| T25 |
168-169 |
-LRB- |
denotes |
( |
| T26 |
169-173 |
NNS |
denotes |
CoVs |
| T27 |
173-174 |
-RRB- |
denotes |
) |
| T28 |
175-178 |
VBP |
denotes |
are |
| T29 |
179-187 |
JJ |
denotes |
zoonotic |
| T30 |
188-197 |
NNS |
denotes |
pathogens |
| T31 |
198-202 |
IN |
denotes |
with |
| T32 |
203-207 |
JJ |
denotes |
high |
| T33 |
208-216 |
NN |
denotes |
fatality |
| T34 |
217-222 |
NNS |
denotes |
rates |
| T35 |
223-226 |
CC |
denotes |
and |
| T36 |
227-235 |
JJ |
denotes |
pandemic |
| T37 |
236-245 |
NN |
denotes |
potential |
| T38 |
247-254 |
NN |
denotes |
Vaccine |
| T39 |
255-266 |
NN |
denotes |
development |
| R10 |
T12 |
T13 |
arg1Of |
syndrome,( |
| R11 |
T14 |
T13 |
arg2Of |
SARS,( |
| R12 |
T15 |
T13 |
arg3Of |
),( |
| R13 |
T12 |
T16 |
arg1Of |
syndrome,and |
| R14 |
T20 |
T16 |
arg2Of |
syndrome,and |
| R15 |
T18 |
T17 |
arg1Of |
East,Middle |
| R16 |
T20 |
T18 |
arg1Of |
syndrome,East |
| R17 |
T20 |
T19 |
arg1Of |
syndrome,respiratory |
| R18 |
T20 |
T21 |
arg1Of |
syndrome,( |
| R19 |
T22 |
T21 |
arg2Of |
MERS,( |
| R2 |
T4 |
T2 |
arg1Of |
shields,coronavirus |
| R20 |
T23 |
T21 |
arg3Of |
),( |
| R21 |
T28 |
T24 |
arg1Of |
are,coronaviruses |
| R22 |
T24 |
T25 |
arg1Of |
coronaviruses,( |
| R23 |
T26 |
T25 |
arg2Of |
CoVs,( |
| R24 |
T27 |
T25 |
arg3Of |
),( |
| R25 |
T16 |
T28 |
arg1Of |
and,are |
| R26 |
T30 |
T28 |
arg2Of |
pathogens,are |
| R27 |
T30 |
T29 |
arg1Of |
pathogens,zoonotic |
| R28 |
T30 |
T31 |
arg1Of |
pathogens,with |
| R29 |
T35 |
T31 |
arg2Of |
and,with |
| R3 |
T4 |
T3 |
arg1Of |
shields,glycan |
| R30 |
T34 |
T32 |
arg1Of |
rates,high |
| R31 |
T34 |
T33 |
arg1Of |
rates,fatality |
| R32 |
T34 |
T35 |
arg1Of |
rates,and |
| R33 |
T37 |
T35 |
arg2Of |
potential,and |
| R34 |
T37 |
T36 |
arg1Of |
potential,pandemic |
| R35 |
T39 |
T38 |
arg1Of |
development,Vaccine |
| R5 |
T7 |
T5 |
arg2Of |
glycosylation,despite |
| R6 |
T7 |
T6 |
arg1Of |
glycosylation,extensive |
| R7 |
T12 |
T9 |
arg1Of |
syndrome,Severe |
| R8 |
T12 |
T10 |
arg1Of |
syndrome,acute |
| R9 |
T12 |
T11 |
arg1Of |
syndrome,respiratory |
